Fcway | 223699-45-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: Fcway
• 英文别名: 4-fluoro-N-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-N-pyridin-2-ylcyclohexane-1-carboxamide
• CAS: 223699-45-4
• 化学式: C₂₅H₃₃FN₄O₂
• 分子量: 440.6
• InChiKey: JQSMVIQRTYWIED-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  32
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  48.9
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• METHOD FOR DETECTING ALZHEIMER"S DISEASE AND OTHER FORMS OF DEMENTIA, AND MEASURING THEIR PROGRESSION
  申请人：The Regents of the University of California System

  公开号：EP1768705A2

  公开（公告）日：2007-04-04
• EP1768705A4
  申请人：——

  公开号：EP1768705A4

  公开（公告）日：2008-01-23
• Method for Detecting Alzheimer's Disease and other Forms of Dementia, and Measuring Their Progression
  申请人：Barrio R. Jorge

  公开号：US20070218002A1

  公开（公告）日：2007-09-20

  The invention provides a method for detecting or monitoring Alzheimer's disease and other forms of dementia using positron emission tomography (PET) or single-photon emission computed tomagraphy (SPECT) and radiolabeled, serotonin 5-HT 1A receptor-specific tracers (such as [F-18]MPPF, [F-18]FCWAY, [C-11]WAY-100635, and other radiolabeled compounds having agonistic or antagonistic effect on serotonin receptors), for detection or monitoring of pathological changes (i.e., neuronal cell loss) associated with dementia.
• [EN] METHOD FOR DETECTING ALZHEIMER'S DISEASE AND OTHER FORMS OF DEMENTIA, AND MEASURING THEIR PROGRESSION<br/>[FR] TECHNIQUE DE DETECTION DE LA MALADIE D'ALZHEIMER ET D'AUTRES FORMES DE DEMENCE ET MESURE DE LEUR PROGRESSION
  申请人：UNIV CALIFORNIA

  公开号：WO2005121796A2

  公开（公告）日：2005-12-22

  The invention provides a method for detecting or monitoring Alzheimer's disease and other forms of dementia using positron emission tomography (PET) or single-photon emission computed tomagraphy (SPECT) and radiolabeled, serotonin 5-HT1A receptor­-specific tracers (such as [F-18]MPPF, [F-18]FCWAY, [C-11]WAY-100635, and other radiolabeled compounds having agonistic or antagonistic effect on serotonin receptors), for detection or monitoring of pathological changes (i.e., neuronal cell loss) associated with dementia.